Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease
NCT06541691
Arterial Occlusive Diseases, Arteriosclerosis
Tehran, Tehran Province, Iran
View Trial DetailsNCT Number: NCT02143102
The investigators use MRI and/or CT to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an endarterectomy of the aforementioned vascular beds as part of their routine clinical care.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
West Jefferson Medical Center, Marrero, Louisiana, United States
The investigators hypothesize that in vivo MRI and/or CT examinations of patients, when suitably acquired and analyzed with the vascuCAP™ analysis software, can provide a sufficiently accurate profile of plaque characteristics to provide an objective basis for patient management. Study subjects include patients undergoing endarterectomies to mitigate their clinical risk or symptoms for conditions including stroke, claudication, and critical limb ischemia. The endarterectomy specimens removed at surgery will allow a direct comparison between the MRI information obtained prior to the surgery and the histopathological analyses of the arterial specimens. The vascuCAP™ measurements of structural and functional features of the arterial wall will be performed in patients undergoing endarterectomy. Measured results will be compared in a blinded fashion with histology to assess performance of plaque profiling and build a pilot prediction model for risk scoring.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Individuals must meet one of the following inclusion criteria in order to be eligible to participate in the study:
Exclusion criteria
Time frame: Assessed on tissue samples collected within 30 days of non-invasive imaging
Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)
Time frame: Assessed on tissue samples collected within 30 days of non-invasive imaging
Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)
Elucid Bioimaging Inc.
Industry
vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy
Acronym: Q-CAMP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06541691
Arterial Occlusive Diseases, Arteriosclerosis
Tehran, Tehran Province, Iran
View Trial DetailsNCT03395509
Aging, Aneurysm
Viborg, Denmark
View Trial DetailsNCT03982420
Arterial Occlusive Diseases, Brain Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT04053166
Brain Diseases, Cardiovascular Diseases
Bron, France
View Trial Details